The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Ankur Dhingra, insider at CareDx

Ankur Dhingra Insider Information

CFO of CareDx
Ankur brings over 25 years of finance and accounting experience gained in the Life Sciences industry. Before joining CareDx, Ankur spent 18 years at Agilent Technologies in various finance and business management roles. Most recently, he was Vice President of Investor Relations and prior to that Group CFO for Agilent’s Life Sciences and Applied Markets business. Ankur has demonstrated a track record of success scaling businesses by executing and influencing growth-oriented business strategies, expanding margins and deploying M&A policies. He has extensive experience managing global teams of finance and accounting professionals. Ankur is a Chartered Accountant from The Institute of Chartered Accountants of India.

How old is Ankur Dhingra?

Mr. Dhingra is currently 46 years old. There are 4 older executives and no younger executives at CareDx. The oldest executive at CareDx is Dr. Peter Maag Ph.D., Exec. Director, who is 55 years old. Learn More on Ankur Dhingra's age.

How do I contact Ankur Dhingra?

The corporate mailing address for Mr. Dhingra and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected] Learn More on Ankur Dhingra's contact information.

Has Ankur Dhingra been buying or selling shares of CareDx?

Ankur Dhingra has not been actively trading shares of CareDx during the past quarter. Most recently, on Monday, July 4th, 0 shares of BMO Capital Markets stock. Learn More on Ankur Dhingra's trading history.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.

Are insiders buying or selling shares of CareDx?

In the last twelve months, CareDx insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $211,700.00. In the last twelve months, insiders at the sold shares 27 times. They sold a total of 156,443 shares worth more than $8,087,835.54. The most recent insider tranaction occured on May, 11th when Director Grace Colon sold 5,179 shares worth more than $119,168.79. Insiders at CareDx own 4.6 % of the company. Learn More about insider trades at CareDx.

Information on this page was last updated on 5/11/2022.

Ankur Dhingra Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2021Buy5,000$42.34$211,700.00View SEC Filing Icon  
See Full Table

Ankur Dhingra Buying and Selling Activity at CareDx

This chart shows Ankur Dhingra's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $22.41
Low: $21.57
High: $22.50

50 Day Range

MA: $25.05
Low: $20.49
High: $34.07

2 Week Range

Now: $22.41
Low: $19.34
High: $92.55

Volume

55,510 shs

Average Volume

817,234 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!